Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI), a leading developer of stem cell technologies, is committed to providing treatments for neurodegenerative diseases that are currently incurable. The company’s focus is on developing NTF cells from the patient’s own bone marrow to treat, Parkinson, ALS, and Spinal Cord Injury. The Brainstorm management and scientific teams are devoted to the company’s mission to regenerate the mind in their lifetime. For further information, visit the Company’s web site at www.brainstorm-cell.com.
- 17 years ago
QualityStocks
Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…